A5028219286- Trypanosoma species research and implications
- Research on Leishmaniasis Studies
- Synthesis and Biological Evaluation
- Pregnancy and Medication Impact
- Pharmaceutical studies and practices
- Cystic Fibrosis Research Advances
- Pharmacological Effects and Toxicity Studies
- Prenatal Substance Exposure Effects
- Breastfeeding Practices and Influences
- Forensic Toxicology and Drug Analysis
- Pregnancy and preeclampsia studies
- Epilepsy research and treatment
- Parasitic Diseases Research and Treatment
- Parasites and Host Interactions
- Cannabis and Cannabinoid Research
- Drug-Induced Adverse Reactions
- Antibiotics Pharmacokinetics and Efficacy
- Poisoning and overdose treatments
- Drug-Induced Hepatotoxicity and Protection
- Cardiovascular Issues in Pregnancy
- Child and Adolescent Health
- Helminth infection and control
- Maternal Mental Health During Pregnancy and Postpartum
- Escherichia coli research studies
- Pharmaceutical Economics and Policy
Western University
2020-2025
London Health Sciences Centre
2022-2025
Children’s Health Research Institute
2020-2023
Lawson Health Research Institute
2020-2023
Hospital General de Niños Ricardo Gutierrez
2013-2023
Ministerio de Salud
2020-2023
Consejo Nacional de Investigaciones Científicas y Técnicas
2012-2022
Victoria Hospital
2022
Hospital del Niño
2022
Instituto Multidisciplinario de Biología Celular
2020-2021
To report clinical course, etiology, management, and long-term outcomes of children suffering from Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).We conducted a study all pediatric patients with SJS TEN admitted between 2000 2007 to the Hospital for Sick Children Children's Boston, particular attention was paid manifestations, mortality, outcomes.We identified 55 cases (n = 47), 5), SJS/TEN overlap 3). Drugs were as most likely etiologic agent in 29 (53%); antiepileptic...
BACKGROUND: Chagas disease is caused by infection with Trypanosoma cruzi. In adults, treatment benznidazole associated a high incidence of adverse drug reactions (ADRs). However, in infants and children, seems lower decreased severity ADRs, but these effects have not been clearly characterized. OBJECTIVE: We aimed to describe ADRs observed children treated benznidazole. PATIENTS AND METHODS: conducted prospective cohort study Argentina RESULTS: A total 107 diagnosed asymptomatic (mean age:...
Introduction Chagas disease, caused by the parasite Trypanosoma cruzi, can lead to long term cardiac morbidity. Treatment of children with benznidazole is effective, but no pediatric pharmacokinetics data are available and clinical pharmacology information on drug scarce. Patients Methods Prospective population pharmacokinetic (PK) cohort study in 2–12 years old disease treated oral 5–8 mg/kg/day BID for 60 days. (clinicaltrials.gov #NCT00699387). Results Forty were enrolled study. Mean age...
It is currently unknown whether treatment of Chagas disease decreases the risk congenital transmission from previously treated mothers to their infants. In a cohort women with benznidazole, no was observed in newborns. This finding provides support for as early possible.
<h3>Background</h3> Postinfectious bronchiolitis obliterans (BO) is a chronic respiratory disease that usually follows severe adenovirus infection. <h3>Objective</h3> To determine the evolution of pulmonary function and clinical outcome children with postinfectious BO during childhood. <h3>Methods</h3> The study included patients diagnosed in whom at least two spirometries were performed within minimum interval 3 months. <h3>Results</h3> 46 met inclusion criteria. mean (±SD) follow-up period...
ABSTRACT On January 12, 2024 the safety committee of European Medicines Agency (EMA) recommended precautionary measures over a potential risk neurodevelopmental disorders in children born to men treated with valproate. These new recommend patient supervision by specialist management epilepsy, bipolar disorder, or migraine. In United Kingdom, and Healthcare products Regulatory (MHRA) issued far more stringent precaution, warning against prescribing valproate anyone under 55 years age. We,...
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children all stages, but it controversial chronically infected adults. We report the pharmacokinetics and pharmacodynamics six adult patients treated new BNZ formulation (ABARAX®) doses between 2.5-5.5 mg/Kg/day. All one patient had plasmatic concentrations within expected range. finalised nondetectable Trypanosoma cruziquantitative polymerase chain reaction, which remained at month follow-up. Our data...